NVO
HealthcareNovo Nordisk A/S · Biotechnology · $200B
NVO Price History
+8.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Novo Nordisk A/S?
Based on Novo Nordisk A/S's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Unlock Full NVO Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓Detailed 6-pillar UQS breakdown with exact scores
- ✓All 29 metrics with sector-calibrated comparisons
- ✓6 investor presets (Buffett, Munger, Lynch, Wood, Graham, Balanced)
- ✓Watchlist tracking with score alerts
- ✓AI-generated investment perspectives across 6 preset views
- ✓Score history chart with change notifications
Pro Analysis
NVO — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 64.8 | 88.4 | 61.0 | 20.6 | 59.9 | 95.5 | +0.1 |
| May 18, 2026 | 64.7 | 88.2 | 61.0 | 20.6 | 59.9 | 95.6 | +0.1 |
| May 16, 2026 | 64.6 | 88.2 | 61.0 | 20.6 | 59.9 | 94.9 | 0.0 |
| May 14, 2026 | 64.6 | 88.2 | 61.0 | 20.5 | 59.9 | 95.0 | +0.1 |
| May 11, 2026 | 64.5 | 88.4 | 61.0 | 20.5 | 59.9 | 94.1 | -0.1 |
| May 9, 2026 | 64.6 | 88.4 | 61.0 | 20.4 | 59.9 | 94.7 | -2.0 |
| May 7, 2026 | 66.6 | 94.3 | 61.0 | 20.3 | 61.0 | 97.0 | +0.1 |
| May 2, 2026 | 66.5 | 94.3 | 61.0 | 20.3 | 61.0 | 96.8 | -0.1 |
| Apr 24, 2026 | 66.6 | 94.3 | 61.0 | 20.7 | 61.0 | 96.8 | 0.0 |
| Apr 19, 2026 | 66.6 | 94.3 | 61.0 | 20.5 | 61.0 | 96.8 | 0.0 |
NVO — Pillar Breakdown
Quality
— 88.4/100 (25%)Novo Nordisk A/S demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 20.6/100 (20%)Novo Nordisk A/S faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 59.9/100 (15%)Novo Nordisk A/S maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 95.4/100 (15%)Novo Nordisk A/S appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
Enterprise value multiple relative to sector median.
Moat
— 61/100 (25%)Novo Nordisk A/S has meaningful competitive advantages that should protect its market position. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for NVO.
Score Composition
Financial Data
More Stock Analysis
How is the NVO UQS Score Calculated?
The UQS (Unified Quality Score) for Novo Nordisk A/S is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Novo Nordisk A/S's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Novo Nordisk A/S is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.